Welcome to our dedicated page for Mountain Vy Md news (Ticker: MVMDF), a resource for investors and traders seeking the latest updates and insights on Mountain Vy Md stock.
Mountain Valley MD Holdings Inc. reports developments across commercialization of its patented Quicksome™ and Quicksol™ formulation technologies, its licensed Agrarius™ agricultural plant signaling product, and related branded nutraceutical initiatives. News about MVMDF commonly covers nutraceutical product formats, agricultural product evaluations, regional distribution and regulatory work, and applications for husbandry animals and aquatic species.
Company updates also include capital actions such as private placements and shares-for-debt transactions, stock option grants, advisor and board appointments, and shareholder or governance matters tied to its public-company status.
Mountain Valley MD (OTC:MVMDF) reported progress advancing its patented Quicksome™ sublingual delivery platform for compounded peptide applications across North and South America. Over six months, the company completed initial Quicksome formulations for peptides including BPC-157, GHK-Cu, KPV, SNAP-8 and retatrutide and is finalizing dosing.
Quicksome aims to deliver needle-free, room‑temperature sublingual tablets for molecules that often require injection and refrigeration. Prior work with tIPV showed 100% preservation of IPV serotype 2 at 40°C for five days. MVMD is pursuing partnerships and licensing with compounding pharmacies, telehealth and wellness channels.
Mountain Valley MD (OTC: MVMDF) appointed nine advisors across health, agriculture, formulation science, and capital markets and granted 15,100,000 stock options at a $0.06 exercise price. Options vest 20% at grant, 30% at six months, and 50% at 12 months, exercisable for five years.
The advisors bring expertise in product formulation, regulatory strategy, commercialization, and capital markets to support peptide and repurposed-therapeutic development.
Summary not available.
Mountain Valley MD (OTC: MVMDF) closed a non‑brokered unit offering and concurrent shares‑for‑debt transactions on April 15, 2026, raising CAD $2,000,000 via 80,000,000 units at CDN $0.025 and issuing 24,647,058 shares to settle CAD $485,000 of debt. Warrants were issued exercisable at CDN $0.08 for 12 months, with acceleration if CSE VWAP ≥ $0.12 for ten consecutive days. Securities are subject to a four‑month and one‑day hold expiring August 15, 2026.
Mountain Valley MD (OTC: MVMDF) announced a strategic non-brokered private placement of units to raise up to CAD $2,000,000 and concurrent shares-for-debt transactions to settle CAD $485,000. The Offering is for up to 80,000,000 Units at CDN $0.025 each; each Unit includes one warrant exercisable at CDN $0.08 for 12 months. The company expects to close in April 2026, subject to CSE approval and customary resale hold periods.
Mountain Valley MD (OTCQB: MVMDF) provided a year-end business update on December 24, 2025, reporting commercialization progress across three platforms: Quicksome nutraceutical delivery, Agrarius agricultural plant signaling, and Quicksol/Soluvec for husbandry and aquaculture.
Key disclosed outcomes include scaled production and retail activity for Quicksome-based nutraceuticals, multiple Agrarius trials showing double-digit yield gains in citrus and row crops, and Soluvec 1% demonstrating nine-month stability but limited royalty revenue to date.
Mountain Valley MD (OTC:MVMDF) reported positive Agrarius agricultural trial results from Brazil and Colombia on December 1, 2025, showing measurable yield and plant‑health gains across multiple crops. Key highlights include a 49% yield increase in Valencia oranges and ~15% (125 boxes/ha) improvement in Hamlin oranges, plus observed reduction in visible HLB symptoms. Potato trials showed 18.49% higher productivity; corn trials reported 14.8% and 11.2% gains. Colombian pasture trials demonstrated improved regrowth and nutritional quality, with final analysis expected in early 2026. The company positions Agrarius for scaled commercialization across citrus, row crops, and forage systems.
Mountain Valley MD (OTCQB:MVMDF) provided a comprehensive business update across its three core technology divisions. The company's Quicksome™ nutraceutical division reported progress with its U.S.-based GMP manufacturer, including USD $193,000 in Q2 2025 sales through licensee Circadian Wellness Corp.
In agriculture, the company's Agrarius technology demonstrated significant yield improvements in field trials: 14.8% increase in corn yield, 10% in sugarcane, and 18.49% in potatoes. The company expanded trials across multiple crops and secured regulatory approvals in several Latin American countries.
The Soluvec™ 1% division reported production of 200 tonnes of coated fish feed in Bangladesh, though royalty revenues were below expectations due to cyclone impact. MVMD is pursuing patent protection in 12 additional markets and plans expansion into Latin America.
Mountain Valley MD Holdings (OTCQB: MVMDF) has announced changes to its Board of Directors. The company appointed David Batchelor, a seasoned organizational strategist with over 25 years of experience in business transformation and performance improvement.
Batchelor brings extensive experience working with global leaders like Cisco, Coca-Cola, IBM, Merck, Bayer, and Johnson & Johnson. He holds a Master's degree in Distributed Learning and has held faculty positions at Schulich Executive Education Centre and Royal Roads University.
The company also announced the resignations of directors Kevin Puloski and Nancy Richardson. These board changes align with MVMD's focus on growth, commercialization, and disciplined capital deployment.
Mountain Valley MD Holdings (MVMD) provided a year-end update on its commercialization progress across three core areas: Nutraceuticals, Agriculture, and Husbandry Animals/Aquatic Species. In Nutraceuticals, the company advanced its Quicksome™ technology through partnerships and product developments, including an OUD formulation and testosterone products. The agriculture division expanded its Agrarius technology presence, securing registrations in multiple countries and implementing a Performance Guarantee Program. In the Husbandry/Aquatic segment, their Soluvec™ 1% product achieved initial sales of 100 tonnes of coated fish feed in Bangladesh, with manufacturing resuming in November 2024 after cyclone-related disruptions.